Skip to main
IDXX

IDEXX Laboratories (IDXX) Stock Forecast & Price Target

IDEXX Laboratories (IDXX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 22%
Buy 44%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

IDEXX Laboratories has established a robust customer retention rate of approximately 97%, enhancing the predictability of its revenue and earnings streams. The company has also achieved a compounded annual growth rate (CAGR) of around 16% in organic consumables recurring revenue from 2016 to 2022, showcasing its ability to drive consistent revenue growth. Additionally, customers that utilize the full suite of IDEXX's offerings experience 3.5 times higher growth across various testing categories, indicating the potential for accelerated adoption and market expansion as pet patient visits recover.

Bears say

IDEXX Laboratories has reported a consecutive decline in clinical vet visits for three consecutive quarters, culminating in a year-over-year decrease of 1.7% in Q4'25, which raises concerns over the demand for its diagnostic products and services. The company anticipates a further decline of 200 basis points in end market pet visits in 2026, primarily attributed to economic pressures on lower-income pet owners, potentially restricting demand for IDEXX's offerings. Furthermore, any adverse developments regarding product lines or economic hardships affecting customers may exacerbate revenue slowdowns, placing additional strain on the company's financial outlook.

IDEXX Laboratories (IDXX) has been analyzed by 9 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 44% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of IDEXX Laboratories and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About IDEXX Laboratories (IDXX) Forecast

Analysts have given IDEXX Laboratories (IDXX) a Buy based on their latest research and market trends.

According to 9 analysts, IDEXX Laboratories (IDXX) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $715, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $715, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

IDEXX Laboratories (IDXX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.